The Federal Reserve's cautious Beige Book may have been a small catalyst to keep a lid on the market, but the real weakness was after the 10-Year Treasury auction came in very weak and 10-year Treasury rates flirted with 4%. Higher draw-downs in oil inventories also kept energy prices higher. Here were today's unofficial closing bell levels:

Dow 8,739.02 -24.04 (-0.27%)
S&P 500 939.15 -3.28 (-0.35%)
Nasdaq 1,853.08 -7.05 (-0.38%)

Top Analyst Upgrades
Top Analyst Downgrades

Today was one of those days where the overall market direction never felt entrenched nor felt certain. The news of ten banks getting to pay back TARP funds created mixed reactions, as the news was expected. Positive guidance from a chip leader may have kept the wheels on the cart for technology stocks. Oil also spent much of the day flirting with the $70 per barrel mark.

With the swings we are seeing from positive to negative, it is just further evidence that there is a battleground between bulls and bears forming. So far the bulls are managing to keep the high ground. Here are today's unofficial closing bell levels:

DJIA
S&P500
NASDAQ

Top Analyst Upgrades
Top Analyst Downgrades

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Bristol-Myers Squibb Co. (NYSE: BMY) Q1 profit fell despite strong sales of Plavix and Abilify.
• Check Point Software Technologies Inc. (NASDAQ: CHKP) was downgraded based on its guidance.
• Domino's Pizza Inc. (NYSE: DPZ) strong Q1 results were boosted by early debt retirement.
• DreamWorks Animation SKG Inc. (NYSE: DWA) strong Q1 results were driven by Madagascar 2.
• Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) Q1 results led to an analyst's downgrade.
• E*Trade Financial Corp. (NASDAQ: ETFC) widened its Q1 loss, sending shares sharply lower.

Look for Sequenom, Inc. (NASDAQ: SQNM) to be smacked hard by selling pressure today. Late Wednesday, the company reported that improper handling of research and development test data and results by its employees has delayed the launch of its Down's Syndrome test. Sequenom said it's forming a special committee to investigate employee activity related to the tainted test data.

The company's SEQureDx tests the DNA of a fetus, via the mother's blood, in order to determine whether their blood groups are compatible. Although Sequenom can no longer rely on previously announced test data and results, Chief Executive Harry Stylli asserted, "We are not back at square one" on a conference call.

Intermune (NASDAQ: ITMN) closed at $11.72. ITMN's Pirfenidone Capacity data is expected soon. ITMN February 12.5 straddle is priced at $7.40, April 12.5 straddle is at $9.80 and July 12.5 straddle is priced at $14.10 according to Track Data, suggesting large price movement.

Sequenom (NASDAQ: SQNM) closed at $23.09. SQNM will present Down's syndrome data after the market close today. SQNM February option implied volatility is at140; March is at 120; above its 26-week average of 103, according to Track Data, suggesting larger price movement.

Sequenom (NASDAQ: SQNM) makes the MassARRAY system, a nucleic acid analysis platform that identifies and quantifies genetic target materials. The system is composed of electronic analysis equipment, related software and various consumables. It is used in biomedical research, livestock testing, oncology diagnoses, molecular medicine, noninvasive prenatal testing, and infectious disease identification. Customers include clinical research laboratories, biotechnology concerns, and universities.

The company surprised the Street last week, when it announced a successful trial of its prenatal test used to detect Down-syndrome in a mother's blood. In blinded studies involving 200 clinical samples, Sequenom's proprietary test identified all Down-syndrome samples with no false positives. The company pointed out that current testing options have a detection rate of 70-90%, with false-positive rates as high as 5%. Management said it will start a study of several thousand samples in the fourth quarter, in preparation for a U.S. launch of the test in the first half of 2009.

MOST NOTEWORTHY: AU Optronics, General Steel and Sequenom were today's noteworthy initiations:

• Jefferies initiated AU Optronics (NYSE: AUO) with a Buy rating and $25 target and believes LCD trends will be healthy in 2008 despite a soft economy.
  
• General Steel (NYSE: GSI) shares were started at Merriman with a Buy rating, as the firm believes strong demand for steel in China should last for years and finds the valuation attractive at current levels.
  
• Cantor believes Sequenom (NASDAQ: SQNM) is positioned to establish sustainable market leadership as a provider of genome analytical products and molecular diagnostics. Shares were assumed with a Buy rating and $12 target.

OTHER INITIATIONS:

• UBS initiated Altria Group (NYSE: MO) with a Buy rating and $30 target.
  
• Canaccord Adams assumed Drugstore.com (NASDAQ: DSCM) with a Buy rating and $3.50 target.
  
• Goldman Sachs initiated DirecTV (NASDAQ: DTV) with a Buy rating and $30 target.

MOST NOTEWORTHY: Big 5 Sporting Goods (BGFV), Nutrition 21 (NXXI), Sonic Solutions (SNIC), AeroGrow (AERO) and Sequenom (SQNM) were today's noteworthy initiations:

• Nollenberger believes Big 5 Sporting Goods' (NASDAQ: BGFV) shares are fairly valued and would likely get more constructive near the $20 level and initiated shares with a Neutral rating.

• ThinkEquity said Nutrition 21 (NASDAQ: NXXI) has a number of clinically proven nutritional supplements that target the rapidly growing obesity and diabetes markets, and initiated shares with a Buy rating.

• SMH Capital initiated shares of Sonic Solutions (NASDQ: SNIC) with a Buy rating, on the belief that shares have been oversold.

• ThinkEquity is positive on AeroGrow's (NASDAQ: AERO) proprietary aeroponic technology and recurring revenue model and initiated shares with a Buy rating.

• Leerink Swann started shares of Sequenom (NASDAQ: SQNM) with an Outperform rating as MEDACorp researchers are positive regarding the company's MassARRAY system for genetic analysis, which is well-positioned for growth in follow-on SNP fine-mapping studies; Leerink anticipates in 2008, the company will launch iPLEX 3, which is currently in development, and reduce the cost of acquiring fine-mapping SNP data...

OTHER INITIATIONS:

• Dover (NYSE: DOV) was initiated at Morgan Stanley with an Overweight rating.

• Merrill started Akamai (NASDAQ: AKAM) with a Neutral rating.

• Pacific Crest started Wipro Ltd (NYSE: WIT) with a Sector perform.

• Susquehanna initiated Herman Miller (NASDAQ: MLHR) with a Positive rating.

• RBC Capital initiated Warren Resources (NASDAQ: WRES) with an Outperform rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).